{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:11:43Z","timestamp":1790691103865,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"am","delay-in-days":278,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006379","name":"Office of Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","award":["I01-BX004220"],"award-info":[{"award-number":["I01-BX004220"]}],"id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Research Career Scientist Award","award":["IK6BX004016"],"award-info":[{"award-number":["IK6BX004016"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.cellsig.2019.109506","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T19:45:35Z","timestamp":1576611935000},"page":"109506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"special_numbering":"C","title":["Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition"],"prefix":"10.1016","volume":"68","author":[{"given":"Nitin A.","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea J.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Belenchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annayya R.","family":"Aroor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Noda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Siebenlist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-5354","authenticated-orcid":false,"given":"Bysani","family":"Chandrasekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-9995","authenticated-orcid":false,"given":"Vincent G.","family":"DeMarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cellsig.2019.109506_bb0005","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.cellsig.2019.109506_bb0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.2040-1124.2010.00071.x","article-title":"Polyol pathway and diabetic nephropathy revisited: early tubular cell changes and glomerulopathy in diabetic mice overexpressing human aldose reductase","volume":"2","author":"Hashimoto","year":"2011","journal-title":"J. Diabetes Investig."},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0015","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/ame2.12001","article-title":"Redox imbalance stress in diabetes mellitus: role of the polyol pathway","volume":"1","author":"Yan","year":"2018","journal-title":"Anim. Model Exp. Med."},{"issue":"1\u20132","key":"10.1016\/j.cellsig.2019.109506_bb0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2013.02.005","article-title":"Resistance to insulin and kidney disease in the cardiorenal metabolic syndrome; role for angiotensin II","volume":"378","author":"Nistala","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"issue":"8","key":"10.1016\/j.cellsig.2019.109506_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/nu11081748","article-title":"The modern Western diet rich in advanced glycation end-products (AGEs): an overview of its impact on obesity and early progression of renal pathology","volume":"11","author":"Bettiga","year":"2019","journal-title":"Nutrients"},{"issue":"6","key":"10.1016\/j.cellsig.2019.109506_bb0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s40620-017-0423-9","article-title":"A more tubulocentric view of diabetic kidney disease","volume":"30","author":"Zeni","year":"2017","journal-title":"J. Nephrol."},{"issue":"5","key":"10.1016\/j.cellsig.2019.109506_bb0035","doi-asserted-by":"crossref","DOI":"10.1152\/ajpregu.00809.2010","article-title":"The proximal tubule in the pathophysiology of the diabetic kidney","volume":"300","author":"Vallon","year":"2011","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"issue":"2","key":"10.1016\/j.cellsig.2019.109506_bb0040","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0045","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1681\/ASN.2010030246","article-title":"SGLT2 mediates glucose reabsorption in the early proximal tubule","volume":"22","author":"Vallon","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"4","key":"10.1016\/j.cellsig.2019.109506_bb0055","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.239","article-title":"Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose-induced oxidative stress in type 1 diabetic mice","volume":"4","author":"Hatanaka","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"issue":"4","key":"10.1016\/j.cellsig.2019.109506_bb0060","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4093\/dmj.2017.0095","article-title":"Effect of Empagliflozin, a selective sodium-glucose Cotransporter 2 inhibitor, on kidney and peripheral nerves in Streptozotocin-induced diabetic rats","volume":"42","author":"Lee","year":"2018","journal-title":"Diabetes Metab. J."},{"issue":"5","key":"10.1016\/j.cellsig.2019.109506_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051083","article-title":"SGLT2 inhibitors as a therapeutic option for diabetic nephropathy","volume":"18","author":"Kawanami","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cellsig.2019.109506_bb0070","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0075","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0080","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.cellsig.2019.109506_bb0085","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005875","article-title":"Empagliflozin improves kidney outcomes in patients with or without heart failure","volume":"12","author":"Butler","year":"2019","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.cellsig.2019.109506_bb0090","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.cellsig.2019.109506_bb0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.kint.2019.02.033","article-title":"Analysis from the EMPA-REG OUTCOME((R)) trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics","volume":"96","author":"Mayer","year":"2019","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0100","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.yjmcc.2013.09.015","article-title":"Angiotensin II stimulates cardiac fibroblast migration via the differential regulation of matrixins and RECK","volume":"65","author":"Siddesha","year":"2013","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"10","key":"10.1016\/j.cellsig.2019.109506_bb0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/hr.2016.54","article-title":"Histone deacetyltransferase inhibitors Trichostatin A and Mocetinostat differentially regulate MMP9, IL-18 and RECK expression, and attenuate angiotensin II-induced cardiac fibroblast migration and proliferation","volume":"39","author":"Somanna","year":"2016","journal-title":"Hypertens. Res."},{"issue":"6","key":"10.1016\/j.cellsig.2019.109506_bb0115","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0092-8674(01)00597-9","article-title":"The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis","volume":"107","author":"Oh","year":"2001","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cellsig.2012.10.009","article-title":"CIKS (Act1 or TRAF3IP2) mediates high glucose-induced endothelial dysfunction","volume":"25","author":"Venkatesan","year":"2013","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellsig.2019.109506_bb0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.freeradbiomed.2014.02.014","article-title":"OxLDL induces endothelial dysfunction and death via TRAF3IP2: inhibition by HDL3 and AMPK activators","volume":"70","author":"Valente","year":"2014","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.cellsig.2019.109506_bb0130","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1016\/j.cellsig.2013.07.013","article-title":"TRAF3IP2 mediates interleukin-18-induced cardiac fibroblast migration and differentiation","volume":"25","author":"Valente","year":"2013","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.cellsig.2019.109506_bb0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.cellsig.2014.01.005","article-title":"Docosahexaenoic acid reverses angiotensin II-induced RECK suppression and cardiac fibroblast migration","volume":"26","author":"Siddesha","year":"2014","journal-title":"Cell. Signal."},{"key":"10.1016\/j.cellsig.2019.109506_bb0140","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yjmcc.2016.07.006","article-title":"Metformin inhibits aldosterone-induced cardiac fibroblast activation, migration and proliferation in vitro, and reverses aldosterone+salt-induced cardiac fibrosis in vivo","volume":"98","author":"Mummidi","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0145","doi-asserted-by":"crossref","first-page":"H52","DOI":"10.1152\/ajpheart.00478.2017","article-title":"TRAF3IP2 mediates high glucose-induced endothelin-1 production as well as endothelin-1-induced inflammation in endothelial cells","volume":"314","author":"Padilla","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0150","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1074\/jbc.M116.764522","article-title":"Targeting TRAF3IP2 by genetic and interventional approaches inhibits ischemia\/reperfusion-induced myocardial injury","volume":"292","author":"Erickson","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1590\/S0100-879X2008005000049","article-title":"The role of stress-activated protein kinase signaling in renal pathophysiology","volume":"42","author":"Ma","year":"2009","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"7","key":"10.1016\/j.cellsig.2019.109506_bb0160","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00125-004-1437-0","article-title":"Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy","volume":"47","author":"Adhikary","year":"2004","journal-title":"Diabetologia"},{"issue":"10","key":"10.1016\/j.cellsig.2019.109506_bb0165","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.4049\/jimmunol.179.10.7101","article-title":"MAPK p38 regulates transcriptional activity of NF-kappaB in primary human astrocytes via acetylation of p65","volume":"179","author":"Saha","year":"2007","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.cellsig.2019.109506_bb0170","doi-asserted-by":"crossref","first-page":"22242","DOI":"10.1002\/jcp.28792","article-title":"RECK suppresses interleukin-17\/TRAF3IP2-mediated MMP-13 activation and human aortic smooth muscle cell migration and proliferation","volume":"234","author":"Mummidi","year":"2019","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.cellsig.2019.109506_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031060","article-title":"Up-regulation of microRNA-21 correlates with lower kidney cancer survival","volume":"7","author":"Zaman","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.cellsig.2019.109506_bb0180","doi-asserted-by":"crossref","first-page":"F793","DOI":"10.1152\/ajprenal.00273.2011","article-title":"Identification of a microRNA signature in renal fibrosis: role of miR-21","volume":"301","author":"Zarjou","year":"2011","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"3","key":"10.1016\/j.cellsig.2019.109506_bb0185","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000499876","article-title":"Matrix Metalloproteinases in renal diseases: a critical appraisal","volume":"44","author":"Zakiyanov","year":"2019","journal-title":"Kidney Blood Press Res."},{"issue":"3","key":"10.1016\/j.cellsig.2019.109506_bb0190","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5527\/wjn.v2.i3.84","article-title":"Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseases","volume":"2","author":"Zhao","year":"2013","journal-title":"World J. Nephrol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0195","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4093\/dmj.2017.0091","article-title":"Glycated albumin is a more useful glycation index than HbA1c for reflecting renal tubulopathy in subjects with early diabetic kidney disease","volume":"42","author":"Huh","year":"2018","journal-title":"Diabetes Metab. J."},{"key":"10.1016\/j.cellsig.2019.109506_bb0200","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.freeradbiomed.2019.06.023","article-title":"Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes","volume":"144","author":"Martinez Fernandez","year":"2019","journal-title":"Free Radic. Biol. Med."},{"issue":"11","key":"10.1016\/j.cellsig.2019.109506_bb0205","first-page":"1094","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"374","author":"Zinman","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.cellsig.2019.109506_bb0210","doi-asserted-by":"crossref","first-page":"10494","DOI":"10.1073\/pnas.190245697","article-title":"CIKS, a connection to Ikappa B kinase and stress-activated protein kinase","volume":"97","author":"Leonardi","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"9","key":"10.1016\/j.cellsig.2019.109506_bb0215","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1681\/ASN.2015070748","article-title":"Tubular epithelial NF-kappaB activity regulates ischemic AKI","volume":"27","author":"Marko","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.cellsig.2019.109506_bb0220","doi-asserted-by":"crossref","first-page":"F857","DOI":"10.1152\/ajprenal.00547.2010","article-title":"Small interfering RNA targeting IKKbeta prevents renal ischemia-reperfusion injury in rats","volume":"300","author":"Wan","year":"2011","journal-title":"Am. J. Physiol. Renal Physiol."},{"issue":"2","key":"10.1016\/j.cellsig.2019.109506_bb0225","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.kint.2015.12.022","article-title":"Angiopoietin-like protein 2 and kidney fibrosis: lessons from knockout mice","volume":"89","author":"Nishi","year":"2016","journal-title":"Kidney Int."},{"issue":"6","key":"10.1016\/j.cellsig.2019.109506_bb0230","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00592-013-0492-8","article-title":"Regulation of TIMP3 in diabetic nephropathy: a role for microRNAs","volume":"50","author":"Fiorentino","year":"2013","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.cellsig.2019.109506_bb0235","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fendo.2019.00441","article-title":"Dapagliflozin attenuates renal tubulointerstitial fibrosis associated with type 1 diabetes by regulating STAT1\/TGFbeta1 signaling","volume":"10","author":"Huang","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0240","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.yjmcc.2012.04.009","article-title":"CIKS (Act1 or TRAF3IP2) mediates angiotensin-II-induced Interleukin-18 expression, and Nox2-dependent cardiomyocyte hypertrophy","volume":"53","author":"Valente","year":"2012","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"10","key":"10.1016\/j.cellsig.2019.109506_bb0245","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1016\/j.cellsig.2015.07.001","article-title":"Aldosterone-induced cardiomyocyte growth, and fibroblast migration and proliferation are mediated by TRAF3IP2","volume":"27","author":"Somanna","year":"2015","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.cellsig.2019.109506_bb0250","first-page":"131","article-title":"The role of TGF-beta and epithelial-to mesenchymal transition in diabetic nephropathy","volume":"22","author":"Hills","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"issue":"9","key":"10.1016\/j.cellsig.2019.109506_bb0255","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1681\/ASN.2010111168","article-title":"Smad3-mediated upregulation of miR-21 promotes renal fibrosis","volume":"22","author":"Zhong","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.cellsig.2019.109506_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-017-0544-4","article-title":"Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice","volume":"16","author":"Aroor","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.cellsig.2019.109506_bb0265","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.cellsig.2019.109506_bb0270","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose Cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front. Physiol."},{"issue":"10","key":"10.1016\/j.cellsig.2019.109506_bb0275","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1093\/cvr\/cvz105","article-title":"SGLT2 inhibitors: reviving the sodium-hydrogen exchanger cardioprotection hypothesis?","volume":"115","author":"Arjun","year":"2019","journal-title":"Cardiovasc. Res."},{"issue":"9","key":"10.1016\/j.cellsig.2019.109506_bb0280","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose Cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol."},{"issue":"16","key":"10.1016\/j.cellsig.2019.109506_bb0285","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.cellsig.2019.109506_bb0290","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00018-015-1848-8","article-title":"Na+-H+ exchanger-1 (NHE1) regulation in kidney proximal tubule","volume":"72","author":"Parker","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"issue":"5","key":"10.1016\/j.cellsig.2019.109506_bb0295","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.3349\/ymj.2016.57.5.1252","article-title":"Oxidative stress-activated NHE1 is involved in high glucose-induced apoptosis in renal tubular epithelial cells","volume":"57","author":"Wu","year":"2016","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.cellsig.2019.109506_bb0300","doi-asserted-by":"crossref","first-page":"1802036","DOI":"10.1155\/2016\/1802036","article-title":"Inhibition of NA(+)\/H(+) Exchanger 1 attenuates renal dysfunction induced by advanced glycation end products in rats","volume":"2016","author":"Li","year":"2016","journal-title":"J. Diabetes Res."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865681930302X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S089865681930302X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T10:52:56Z","timestamp":1760266376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S089865681930302X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":60,"alternative-id":["S089865681930302X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2019.109506","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2019.109506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109506"}}